Evidence map›Paper›PMID 32812187›Full record

SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020

Is there any potential management against COVID-19? A systematic review and meta-analysis.

Haleh Talaie, Sayed Masoud Hosseini, Maryam Nazari, Yadollah Fakhri, Atieh Mousavizadeh, Hossein Vatanpour, Ali Firoozfar

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 6 pooled it
0.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 6 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Interleukin-1 blocking agents for treating COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Review
  10. Observational
  11. Tocilizumab in COVID-19: enthusiasm vs. evidence.Lung India : official organ of Indian Chest Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Haleh TalaieToxicological Research Center, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Kamali Avenue, south Karegar Street, Tehran, 1333631151, Iran. talaie@sbmu.ac.ir.ORCID http://orcid.org/0000-0002-7430-8134
Sayed Masoud HosseiniDepartments of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam NazariToxicological Research Center, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Kamali Avenue, south Karegar Street, Tehran, 1333631151, Iran.
Yadollah FakhriInfectious and Tropical Diseases Research Center, Hormozgan Heath Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Atieh MousavizadehDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Hossein VatanpourDepartments of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali FiroozfarAnatomy and Physiology Department, Gharmsar University, Gharmsar, Iran.
Shahid Beheshti University of Medical Sciences · IRGhaem Hospital · IRHormozgan University of Medical Sciences · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA recent survey has shown that the COVID-19 pandemic has culminated in dramatical and critical treatment particularly in acute infected patients. In fact, this systematic review-meta-analysis was directly pertained to estimation at the efficient value of some clinical managements to confront the COVID-19 infection.

methodsPubmed, Embase, Scopus, Cochrane, and Scholar databases were searched from inception to July 1, 2020, to identify studies reporting the current treatment process and medications (e.g. hydroxychloroquine, antiviral therapy, convalescent plasma, and immunomodulatory agents) for COVID-19. A random-effects model meta-analysis was performed to calculate the relative risk (RR) with 95% confidence intervals (CI). The outcomes of this study were the frequency of negative conversion cases, clinical improvements, mechanical ventilation demand, intensive care unit (ICU) entry, and mortality. The standard treatment refers to the published guidelines and specialist experience which varies in different articles, and the proposed treatment refers to the kind of interest suggested in the included studies.

resultsA number of 45 articles met the eligibility criteria (out of 6793 articles). Among them, 26 articles involving 3263 patients were included in quantitative analysis. Anti-COVID-19 interventions could significantly increase clinical improvement (RR 1.17, 95% CI 1.08-1.27; I

conclusionBased on our findings, all the included interventions significantly declined the mortality and enhanced clinical improvements with no effect on negative conversion and mechanical ventilation demand. Especially, immunomodulators and plasma therapy showed favorable outcomes. An evaluation on the efficacy of proposed treatment against COVID-19.

Indexed as

Antiviral AgentsCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveImmunologic FactorsIntensive Care UnitsRespiration, ArtificialAntiviral AgentsImmunologic FactorsCOVID-19Meta-analysisOutcomeSARS-CoV-2Treatment

Identifiers

PMID32812187
PMCPMC7434334
OpenAlexW3049269555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.